Angelicin

Angelicin is a furanocoumarin compound that functions as an inhibitor of NF-κB and MAPK signaling pathways, exhibiting anti-inflammatory, antiviral, and antitumor activities. It suppresses the lytic replication of γ-herpesviruses, such as MHV-68, early during viral infection, potentially inhibiting RTA gene expression (IC₅₀=28.95 μM). Angelicin also mitigates inflammation by inhibiting the phosphorylation and nuclear translocation of NF-κB, and the phosphorylation of p38 and JNK. Furthermore, it induces apoptosis in neuroblastoma cells by downregulating anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1, while activating caspase-9 and caspase-3. In Vitro:Angelicin (30-50 μM; 48 h) induced apoptosis in SH-SY5Y cells, causing downregulation of Bcl-2, Bcl-xL, and Mcl-1 protein expression, and activated the cleavage of caspase-9 and caspase-3, leading to apoptosis^[1].
Angelicin (28.95 μM; 48 h) inhibited viral replication in MHV-68-infected BHK21 cells, causing downregulation of viral proteins ORF45 and ORF65 expression, and reduced viral genome replication and RTA mRNA expression^[2].
In Vivo:Angelicin (1, 5, 10 mg/kg; intraperitoneal injection; once, 1 hour before LPS induction) shows anti-inflammatory effects in the LPS-induced acute lung injury model in mice, reducing inflammatory cell infiltration and cytokine production by inhibiting the MAPK and NF-κB pathways^[3].